Key result
Calcium channel blockers' efficacy in managing iron-induced cardiomyopathy is influenced by multiple therapeutic modifiers, according to a systematic review of 21 studies (7 trials, 14 animal studies).
Why the study?
Clinical trials evaluating calcium channel blockers to manage iron-induced cardiomyopathy in transfusion-dependent thalassemia have yielded conflicting results.
Do calcium channel blockers prevent cardiac iron deposition and cardiomyopathy in transfusion-dependent thalassemia?
Systematic Review (n=21)
Do calcium channel blockers prevent cardiac iron deposition and cardiomyopathy in transfusion-dependent thalassemia?
The effectiveness of calcium channel blockers in managing iron-induced cardiomyopathy in thalassemia is influenced by multiple factors, including baseline iron content and interactions with chelators, which must be considered in future trials.
Answers are grounded in this paper and cite their sources.
Account for baseline iron and chelator interactions with CCBs in thalassemia; extends evidence on therapeutic modifiers for future trials.
Calcium channel blockers (CCBs) for long-term (L) and transient (T) calcium channels (LTCC and TTCC) on cardiomyocytes have been suggested to manage iron-induced cardiomyopathy in transfusion-dependent thalassemia patients. However, the results of clinical trials on the effectiveness of CCBs have been conflicting. Here, we systematically reviewed previous studies to investigate the potential factors that could act as therapeutic modifiers and explain these discrepancies. This systematic review was conducted employing the PRISMA guideline to retrieve clinical trials and animal studies investigating the efficacy of CCBs. Studies in the following databases were collected: Web of Science, PubMed, Scopus, Google Scholar, Clinical Trials, Iranian Registry for Clinical Trials, and Cochrane CENTRAL. Keywords included the trade and generic names of various CCBs, thalassemia, and cardiomyopathy. Our Primary search resulted in 297 studies, of which 21 (n = 7 trials and n = 14 animal studies) were further analyzed. The most important parameters that could potentially influence the clinical effectiveness of CCBs in managing iron-induced cardiomyopathy included baseline cardiac iron content, diversity of iron entry routes (LTCCs, TTCCs, DMT-1, etc.), type of CCBs used, iron-induced irreversible functional/structural cardiac changes, iron-Ca2+ joint metabolic dysregulation, deregulated expression of LTCCs and TTCCs, interaction of CCBs with iron chelators, disease-related complications, interactions of CCBs with various supplements used by patients, vitamin D and other nutrient deficiencies, and duration of treatment with CCBs. These items should be considered in future trials to draw more robust conclusions about the effectiveness of CCBs in preventing cardiac iron deposition and associated cardiomyopathy in TDT patients.
No takes yet. Share an insight, caveat, or question.
Bazı et al. (2025) conducted a systematic review in iron-induced cardiomyopathy in transfusion-dependent thalassemia (n=21). Calcium channel blockers was evaluated on factors influencing clinical effectiveness of CCBs. Calcium channel blockers' efficacy in managing iron-induced cardiomyopathy is influenced by multiple therapeutic modifiers, according to a systematic review of 21 studies (7 trials, 14 animal studies).
Synapse has enriched 10 related papers. Consider them for comparative context: